Sign Out
No formal interaction studies with METALYSE and medicinal products commonly administered in patients with acute ischaemic stroke have been performed.
Drugs affecting coagulation/platelet function: Medicinal products that affect coagulation or those that alter platelet function may increase the risk of bleeding, and should therefore be avoided in the first 24 hours after Metalyse treatment for acute ischaemic stroke, see also Contraindications.
ACE Inhibitors: Concomitant treatment with ACE inhibitors may enhance the risk of experiencing a hypersensitivity reaction (see Precautions).
Other medicinal products: Published academic randomised trials involving more than 2,000 patients treated with tenecteplase did not show any clinically relevant interactions with other medicinal products commonly used in patients with AIS.
